Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Elanco Animal Health heads into its November 6 earnings with a notable insider buying cluster, modest short rebuilding, and a Street that remains constructively positioned well above the current price.
The most striking feature of the past two months is the pattern of discretionary insider buying. Five separate open-market purchases hit the tape between early August and late August, none of them under a 10b5-1 plan. Director Lawrence Kurzius led with a $936,000 purchase at $23.40. Director Paul Herendeen added $237,000 at $23.69. The CFO Robert VanHimbergen put in $97,000 at $23.08. Two other insiders also bought. Combined, the net 90-day insider position is positive at roughly $1.47 million across 63,000 shares. That cluster, all at prices above today's $22.36 close, signals that people with direct knowledge of the business saw value at levels the stock has since drifted below.
Short interest has been edging higher, but it tells a measured rather than aggressive story. It now runs at 6.4% of the free float, up about 0.8% over the past week and 1.7% over the past month. At 31.5 million shares short, the position is real but not extreme. More telling is the lending market: availability is very loose, with more than 550% availability relative to current short interest, meaning there are roughly five and a half shares available to borrow for every one already lent out. The cost to borrow has barely moved, holding near 0.52%. These conditions offer no friction to new shorts, but equally provide no squeeze pressure. Options sentiment is calm. The put/call ratio of 0.36 is almost exactly in line with its 20-day average, showing no tilt toward either protection or speculation ahead of earnings.
The Street remains firmly in the bull camp, and the mean price target of $31.00 implies roughly 39% upside from current levels. The most recent analyst actions, both from August following the Q2 print, were target raises: UBS lifted to $33, Keybanc to $30, both maintaining positive ratings. Morgan Stanley, the most cautious active voice with an Equal-Weight, still raised its target to $26 in July. The bull case centres on Befrena, Elanco's new dermatology product, with 83% of veterinarians surveyed saying they are likely to use it and demand reportedly running ahead of supply capacity. Q2 results beat on revenue ($1,368M), adjusted EBITDA ($288M) and EPS ($0.34), and full-year guidance was raised across all key metrics. Bears point to slower-than-expected ramp potential for key blockbusters, K9 population growth near zero, and generic and competitive pressure in key categories. Valuation is not demanding: the P/E sits near 17.9x, down about 1.5 points over the past month, and EV/EBITDA near 13.7x has also drifted lower.
Institutional ownership is concentrated and stable. Dodge and Cox holds roughly 13.5% and has not changed its position since the last report. FMR (Fidelity) added around 3.4 million shares in the most recent quarter to reach approximately 10%, and BlackRock added 1.2 million shares. T. Rowe Price added modestly. None of the 13D/G filings reflect activist intent, all are passive Schedule 13G holders, and no activist has entered the register. The disclosure caveat applies: these stakes are as last reported around the 5% threshold and may have shifted since.
The earnings history is worth noting plainly. Elanco has moved lower on the day of each of its recent prints: down 7.9% after the August 2026 release, and down 5.5% after the prior quarter. The five-day window has also been negative. With the stock already off nearly 9% over the past month and sitting below where insiders bought in August, the next print on November 6 will be the clearest test of whether the Befrena demand signal and raised guidance translate into sustained revenue momentum or whether competitive and weather-related headwinds visible in the bear case are beginning to materialise.
See the live data behind this article on ORTEX.
Open ELAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
